Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Geoff Otto et al.|Nature Medicine|2018Cited by 1.2k
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F. Brown, Paul Mulholland, Matthew Williams et al.|Neuro-Oncology|2018Cited by 83
Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicineYan Li, Jinfeng Zhang, Albert Steppi et al.|Scientific Reports|2017Cited by 57
ESCO2 inhibits tumor metastasis via transcriptionally repressing MMP2 in colorectal cancerXiongbo Guo, Yan Li|Cancer Management and Research|2018Cited by 44